The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Shields Health Solutions
Sole Financial Advisor to Evernorth Health Services, a subsidiary of the Cigna Group, on its announced $3.5 billion investment in Shields Health Solutions
Plena Healthcare
Advising Australian Unity, one of Australia’s largest providers of in-home care services, on its acquisition of Plena Healthcare, a national provider of mobile allied health services within residential aged care and community settings, from Zenitas Healthcare
Carbon Chemicals Group
Advising Shrieve Chemical Company, a portfolio company of Gemspring Capital Management, on the acquisition of Carbon Chemicals Group, a full-service distributor of specialty chemicals, food ingredients, pharmaceutical raw materials, and agriculture products
Markforged Holding Corporation
Advising Nano Dimension, a developer of 3D printing and Additive Manufacturing technologies, predominantly for A&D applications, on its acquisition of Markforged, a developer of digital 3D printing solutions in metal and advanced composites
Desktop Metal, Inc.
Advising Nano Dimension, a developer of 3D printing and Additive Manufacturing technologies, predominantly for A&D applications, on its acquisition of Desktop Metal, a vertically integrated 3D printers, materials and software company and pioneer of several 3D printing technologies
Avail Infrastructure Solutions
Advised Avail Infrastructure Solutions on the sale of its Electrical Products Group, a leading provider of specialized products and solutions designed to support industrial and electrical applications, to nVent Electric plc (NYSE: NVT), a global leader in electrical connection and protection solutions
Renewi plc
Advising Renewi plc, a leading European waste-to-product company, on its £707 million recommended cash offer for its entire issued share capital from a consortium controlled by Macquarie Asset Management and British Columbia Infrastructure Management Corporation (BCI)
Pacific Smiles Group
Advised Pacific Smiles Group Limited, one of Australia’s leading and fastest growing dental service organisations, on its response to multiple private equity proposals and ultimate sale to Genesis Capital by way of off-market takeover
Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)
Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)
Tyman plc
Advised Tyman plc, a leading international supplier of fenestration components and access solutions to the construction industry, on the recommendation of a cash and share acquisition by Quanex, a global NYSE listed manufacturing company serving OEMs in the fenestration, cabinetry, solar, refrigeration and outdoor products markets
EthosEnergy
Advised One Equity Partners, a middle market private equity firm, on the acquisition of EthosEnergy, a global independent turbine and rotating equipment service provider for power and process industries and for aerospace & defense markets
Tegra’s Operating Entities in Honduras, El Salvador, and the U.S.
Advising Tegra, a premier and leading near and onshore apparel manufacturer for sport, team, and performance apparel, on the sale of its operating entities in Honduras, El Salvador, and the U.S. to SAE-A Trading, a vertically integrated textile and apparel garment manufacturer
myHomecare Group
Advising Australian Unity on its acquisition of myHomecare Group
Huntswood CTC Limited
Advised Huntswood CTC Limited, a business process and outsourcing company, on its sale to The Results Companies, LLC (“ResultsCX”), a global Customer Experience Management company backed by ChrysCapital
Clinigen Ltd’s portfolio of Established Medicines
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
Distribuidora Internacional Carmen SAU
Advised Diploma PLC in the acquisition of Distribuidora Internacional Carmen SAU (“DICSA”), a market-leading distributor of fluid power solutions into the European aftermarket
PCAS Canada Inc.
Advised DIC Corporation, a Japanese specialty chemical company, on the acquisition of PCAS Canada Inc., a contract manufacturer of high-quality photoresist polymers, from PCAS SA, a French manufacturer of complex molecules for Life Sciences and Specialty Chemicals markets which is a majority-owned subsidiary of SK Capital-backed Seqens
Distrelec BV
Advised RS Group plc on the acquisiton of Distrelec, a high-service, digital-led distributor of industrial MRO and electronic products
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
Calibre Group’s QuadR Business
Advising Calibre Group, an Australian diversified engineering group, on the sale of its Calibre QuadR business to WSP Global Inc., a leading global engineering and professional services firm
Clinigen Ltd’s Lamda Laboratories
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
David Brown Santasalo
Advised N4 Partners on the sale of David Brown Santasalo (DBS), UK based industrial gear manufacturer, to Stellex Capital Management
Clinigen Ltd’s Proleukin
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
Calibre Group’s Built Environment Business
Advised Calibre Group, a leading Australian provider of sustainable engineering solutions, on the sale of its Built Environment business to Egis S.A., a French headquartered global consulting and engineering services firm owned by Tikehau Capital and Caisse des Dépôts